Objective Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival …
H Tang, Y Xie, M Zhu, J Jia, R Liu, Y Shen… - International Journal …, 2022 - Taylor & Francis
Purpose Ovarian cancer is the most lethal gynecologic malignancy. The combination of paclitaxel (PTX) and carboplatin (CBP) is the first-line remedy for clinical ovarian cancer …
YH Chang, KC Wu, KH Wang, DC Ding - International Journal of …, 2023 - mdpi.com
This study investigated the effects of progesterone receptors A (PRA) and B (PRB) on proliferation, migration, invasion, anchorage-independent growth (AIG), and apoptosis of …
T Okecha, DB Abila, DL Nabbale… - Obstetrics and …, 2024 - Wiley Online Library
Background: BRCA1 gene dysfunction seen in epithelial ovarian carcinomas often results from germline mutations, somatic mutations, and promoter methylation. Identification of …
JW Ryu, HY Shin, HS Kim, GH Han, JW Kim… - Frontiers in …, 2023 - frontiersin.org
Hormones may be key factors driving cancer development, and epidemiological findings suggest that steroid hormones play a crucial role in ovarian tumorigenesis. We …
S Mohan, S Patel, D Barlow, AC Rojas - Advances in Medical Sciences, 2020 - Elsevier
Purpose We investigated N w-hydroxy l-Arginine (NOHA) predictive response in serous ovarian carcinoma based on estrogen-hormone receptor expression status; and assessed …
In der pathologischen Diagnostik ist eine Abgrenzung zwischen primären muzinösen Ovarialkarzinomen und ovariellen Metastasen mit Ursprung in Kolon, Zervix, Pankreas und …
University Teaching Hospital between the 1 January 2004 and 31 December, 2013. Methods: This was a hospital based retrospective study of ovarian surface epithelial …
F Ameli, M Entezarian, N Masir, TG Chin - Journal of Obstetrics …, 2024 - jogcr.com
Background & Objective: The highest mortality rate in gynecologic cancers is attributed to ovarian origin. Expression of the estrogen and progesterone receptors (ER and PR); and …